Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website. # ​Agilex Biolabs ## Sitemaps [XML Sitemap](https://www.agilexbiolabs.com/sitemap_index.xml): Includes all crawlable and indexable pages. ## Posts - [Nearly 30 years of Small Molecule Drug Development from Agilex Biolabs](https://www.agilexbiolabs.com/nearly-30-years-of-small-molecule-drug-development-from-agilex-biolabs/): Agilex Biolabs is celebrating its 29th year as a bioanalytical laboratory, with small molecule bioanalytical services that have extended and evolved across these 3 decades. With almost 30 years of experience with novel chemical entity, regulated bioanalysis, covering a variety of different types of molecules from normal chemical entities to sugars, enantiomers, peptides, oligonucleotides, and metabolites. In addition, we have conducted several chiral projects (where the molecule is handed, so it either has a left or right-handed face) to support drug development programs. - [World-class Small Molecule Support for New Psychedelics Research Projects](https://www.agilexbiolabs.com/world-class-small-molecule-support-for-psychedelics/): For decades before antibody drugs were discovered, small molecule drugs have been used therapeutically. These small molecule drugs - one of the more well regarded being aspirin (which originates from the bark of the willow tree to produce acetylsalicylic acid are quite prevalent in a variety of traditional medicines in many cultures and for many years have been mined by pharmaceutical companies and biotech companies in order to provide therapeutics for novel diseases. - [Meet the Agilex team: a Video Interview with Cameron Smith](https://www.agilexbiolabs.com/meet-the-team-video-cameron/): My name is Cameron Smith. I'm the Chief Business Development Officer here at Agilex Biolabs. I support and lead a team of six business development professionals across Australia, Asia Pacific, and USA. - [Receptor Occupancy Services in Biotherapeutics](https://www.agilexbiolabs.com/receptor-occupancy-in-biotherapeutics/): Receptor occupancy services encompass techniques to measure the binding dynamics between a drug molecule and its target receptor. These techniques affect both in vitro and in vivo analysis. - [The Evolution of Pharmacokinetics for Small Molecules in Bioanalysis](https://www.agilexbiolabs.com/pk-for-small-molecule/): Today, pharmacokinetics (PK) stands as a cornerstone in pharmacology. PK illuminates the intricate processes by which the human body interacts with administered substances. This is particularly the case with small molecules aimed at therapeutic intervention. - [Unlocking Pharmaceutical Research Potential: Agilex as an Ideal Partner for Small- and Large-Molecule Drug Development](https://www.agilexbiolabs.com/agilex-large-and-small-molecule/): Upon entering the intricate and often confusing landscape of pharmaceutical research, companies frequently encounter many challenges. Getting any project to the point of clinical trials requires that everyone on board be aware of the many potential snares along the way. This is especially the case when seeking assistance for both small and large-molecule development. One of the central difficulties lies in the inherent complexity and diversity of these differing molecules. - [Helping to Pioneer a New Era in Individualized, Targeted Immuno-oncology Clinical Trials](https://www.agilexbiolabs.com/individualized-targeted-immuno-oncology-clinical-trials/): From ancient Egypt to the early 19th century, there have been multiple anecdotal reports of tumors disappearing spontaneously; these typically occurred after an infection with a concomitant high fever. As early as 1863, Rudolf Virchow, a German pathologist, began investigating the connection between tumors and inflammation. Working in his lab, Virchow observed that neoplastic tissues were often decorated with leukocytes of the immune system. - [Benefits of Conducting Your Toxicology Studies in Australia](https://www.agilexbiolabs.com/benefits-of-conducting-your-tox-studies-in-australia/): There are many benefits to conducting drug development studies in Australia, especially to timelines and expenses, without having to sacrifice quality. These unique incentives apply to all Research and Development, manufacturing, non-clinical and clinical studies required for the drug development process.  - [Cameron Smith Appointed as Chief Business Development Officer for Agilex Biolabs](https://www.agilexbiolabs.com/cameron-smith-appointed-chief-business-development-officer/): As Agilex Biolabs continues its global expansion and corporate evolution as part of the Healius network, Stephen McIntyre has been selected to take the position of Chief Executive Officer. - [Asking the Right Questions to Avoid Common Pitfalls with Your Molecular Cell & Gene Therapy Project](https://www.agilexbiolabs.com/asking-the-right-questions-to-avoid-common-pitfalls-with-your-molecular-cell-gene-therapy-project/): The rise of Cell and Gene Therapy products is increasingly becoming more prevalent. At Agilex we are seeing more and more of these programs coming forward now. Some might be modulators of a specific mRNA to shut down a protein or production of a protein, or it might be something where a client is using an mRNA method for replacement therapies to address diseases such as muscular dystrophy, for example, wherein dystrophin is dysregulated and the goal is to “switch on” the appropriate protein as opposed to the mutant protein. The solution potential for this growing field seems almost limitless. - [In House PK Data Analysis at Agilex Biolabs: One Year of Growth and Integration](https://www.agilexbiolabs.com/in-house-pk-data-analysis-one-year-on/): Faster reporting, integrated expertise, and growing scientific capability. One year after launching its in-house pharmacokinetic data analysis service, Agilex Biolabs reflects on how an integrated bioanalysis and PK model is helping sponsors accelerate clinical development decisions. - [Same Game, New Rules: Is Immunogenicity Testing Still Fit for Modern Drug Development?](https://www.agilexbiolabs.com/immunogenicity-testing-drug-development/): Immunogenicity testing is due for a rethink, as modern drug development shifts from rigid frameworks to smarter, clinically driven strategies. - [The Promise of Oligonucleotide Therapeutics](https://www.agilexbiolabs.com/oligonucleotide-bioanalysis-challenges-solutions/): Oligonucleotide therapeutics are transforming modern medicine, but analysing them is anything but simple. This article breaks down the three core challenges of oligonucleotide bioanalysis and the regulatory-ready LC-MS strategies required to generate reliable, submission-quality data. - [Agilex Biolabs Expands Flow Cytometry Capabilities with New Laboratory on Brisbane’s QIMR Berghofer Medical Research Institute Campus](https://www.agilexbiolabs.com/agilex-biolabs-brisbane-flow-cytometry-laboratory/): Agilex Biolabs expands with a new Flow Cytometry Laboratory at QIMR Berghofer, boosting speed and precision in clinical research. - [The Brevity of Brevetoxin: Agilex Biolabs Leads South Australia’s Response to the toxic algal bloom crisis with bioanalytical expertise](https://www.agilexbiolabs.com/agilex-biolabs-brevetoxin-crisis/): Agilex Biolabs has been contracted by the South Australian Government to help address the toxic algal bloom affecting parts of South Australia. Our scientists are developing, validating and deploying a liquid chromatography–mass spectrometry (LCMS) method for the rapid quantification of brevetoxins in seafood. This sovereign testing capability will provide assurance to regulators, industry and the public that food remains safe. - [Unlocking the Power of Biomarkers in Early Phase Clinical Trials – A Fit for Purpose Approach](https://www.agilexbiolabs.com/biomarker-revolution-fit-for-purpose-validation-drug-development/): The use of biomarkers in medicine is not new. Long before the rise of modern molecular diagnostics, ancient Egyptians reportedly used a form of pregnancy testing by observing whether barley or wheat seeds sprouted when exposed to a woman's urine. Whilst rudimentary, this early method measured a defined characteristic as an indicator of a biological process. In this sense, it can be seen as one of the earliest recorded uses of a biomarker. - [Reduce Turnaround Times in SAD/MAD Studies: Agilex Launches In-House PK Data Analysis Service](https://www.agilexbiolabs.com/in-house-pk-data-analysis-service/): Agilex Biolabs now offers in-house PK data analysis to complement our industry-leading bioanalytical services - ensuring your program moves seamlessly from sample to insight. - [Regulated Bioanalysis For The Pharmacokinetic Profiling of Cannabinoids and Psychedelics](https://www.agilexbiolabs.com/regulated-bioanalysis-cannabinoids-psychedelics/): Agilex Biolabs collaborated with a biotechnology company conducting a Phase I clinical trial to assess the pharmacokinetics and safety of psilocybin in healthy volunteers. The study required the development and validation of a sensitive and specific LC-MS/MS assay to quantify psilocybin and its active metabolite, psilocin, in human plasma. - [Flow Cytometry in Clinical Trials: Advancing Immunology and Dermatology Research with Agilex Biolabs and Cytek Aurora](https://www.agilexbiolabs.com/flow-cytometry-clinical-trials-cytek-aurora/): The following article focuses on the use of flow cytometry in clinical trials and the use of Agilex Biolab’s new Cytek Aurora spectral flow cytometry platform. The Cytek Aurora platform represents a significant advance over traditional flow cytometry methods, overcoming many of the known shortcomings.  - [The Benefits of ISO 27001 for Agilex Biolabs](https://www.agilexbiolabs.com/the-benefits-of-iso-27001-for-agilex-biolabs-2/): In today's digital age, information security is paramount. At Agilex Biolabs, we understand the importance of safeguarding our data and maintaining the trust of our clients. This is why we have pursued and achieved ISO 27001:2022 certification, an internationally recognized standard for Information Security Management Systems (ISMS).  - [Project Management and Communication at Agilex Biolabs: A Strategic Differentiator in the Bioanalytical Industry](https://www.agilexbiolabs.com/project-management-and-communication-at-agilex-biolabs-a-strategic-differentiator-in-the-bioanalytical-industry/): The bioanalytical and drug development industry is at the forefront of innovation, working tirelessly to bring life-saving therapies to market. In this high-stakes, service-driven sector, the stakes are immense: accelerated timelines, stringent regulatory requirements, and the ever-present demand for quality and accuracy. Amid these challenges, two elements—project management and communication—emerge as critical differentiators. When executed effectively, they can transform service delivery, enhance client satisfaction, and create a competitive edge. This is where Agilex Biolabs excels. With a dedicated project management team managing multi-assay and cross-departmental projects, client management is prioritized, ensuring that your projects are kept on track and communicated effectively every step of the way. - [Want to reduce time and cost of clinical development? A webinar revealing why sponsors are increasingly outsourcing clinical trials to Australia](https://www.agilexbiolabs.com/want-to-reduce-time-and-cost-of-clinical-development-a-webinar-revealing-why-sponsors-are-increasingly-outsourcing-clinical-trials-to-australia/): Research shows that Biotechnology companies have been facing significant challenges – with continual declines in deal making activity and the concentration of limited funding opportunities. For these reasons, there has been increased demand for outsourcing trials to lower the barrier of entry into the clinic. - [Enhancing ELISpot data for your Clinical Immunology Study using Magnetically Isolated Cells: A Case Study](https://www.agilexbiolabs.com/enhancing-elispot-data-for-your-clinical-immunology-study-using-magnetically-isolated-cells-a-case-study/): By Dr. Kurt Sales, CSO - [Agilex achieves certification for isolation and cryopreservation of PBMCs](https://www.agilexbiolabs.com/agilex-achieves-certification-for-isolation-and-cryopreservation-of-pbmcs/): Peripheral Blood Mononuclear Cells (PBMC) are critical for the pharmacodynamic assessment of new drug products. They provide crucial information on how immunomodulatory drugs, designed to target immune cells, function in a clinical trial setting and provide drug developers with that crucial mode of action data required to prove efficacy. - [At Agilex, we can do a whole lot with your Whole Blood!](https://www.agilexbiolabs.com/at-agilex-we-can-do-a-whole-lot-with-your-whole-blood/): The pharmacodynamics of a drug refers to its effect on the body and how it interacts with its target. PBMCs are commonly used in clinical trials to evaluate the pharmacodynamics of a new drug, particularly in trials for biologics, immunotherapies, and vaccines. By isolating PBMCs from blood from patients at different time points during the trial, bioanalytical laboratories can assess how a drug affects immune responses. - [Oligonucleotide Analysis by LC-MS/MS at Agilex Biolabs: Challenges, Solutions and a Case Study.](https://www.agilexbiolabs.com/oligonucleotide-analysis-by-lc-ms-ms-at-agilex-biolabs-challenges-solutions-and-a-case-study/): Oligonucleotides, including small interfering RNA (siRNA) and antisense oligonucleotides (ASO), have gained significant attention in recent years as promising therapeutic agents. With their potential to regulate gene expression, they hold promise for treating a variety of diseases, from cancer to genetic disorders. However, successful development of oligonucleotide-based therapeutics requires precise and reliable bioanalytical methods to quantify and characterize these molecules, ensuring drug quality and therapeutic efficacy. - [Agilex Biolabs, the Perfect Fit for Biotech Companies Navigating Toxicology and Preclinical Safety Testing](https://www.agilexbiolabs.com/agilex-biolabs-the-perfect-fit-for-biotech-companies-navigating-toxicology-and-preclinical-safety-testing/): In the high-stakes world of drug development, biotech companies face unique challenges at every stage - especially in preclinical safety testing, where the stakes are high, and time is of the essence. When it comes to toxicology studies and preclinical safety testing, choosing the right partner can make all the difference. Agilex Biolabs is Australia’s largest Toxicology and Bioanalytical provider, offering the perfect combination of personalized service, flexibility, and specialized expertise, while still having the resources to provide timely, high-quality results - giving sponsors the feel of a CRO with medium sized agility combined with a large CRO capability and scale. In this blog post, we'll explore why Agilex is the right-sized solution for biotech companies in need of toxicology and preclinical safety testing and regulated Bioanalysis in Australia. - [Designing LCMS Studies with the FDA in Mind from the Start](https://www.agilexbiolabs.com/designing-lcms-studies-with-the-fda-in-mind-from-the-start/): Liquid chromatography-mass spectrometry (LCMS) has become an indispensable tool for the pharmaceutical and biotechnology industries. It is powerful, precise, and capable of generating complex datasets that are instrumental in drug development. However, navigating LCMS studies effectively involves more than just technical expertise - it requires anticipating regulatory needs, especially from the U.S. Food and Drug Administration (FDA), right from the onset. - [Agilex, your Australian Toxicology provider with global reach](https://www.agilexbiolabs.com/agilex-your-australian-toxicology-provider-with-global-reach/): By Dr. Kurt Sales, CSO - [Don’t Let a Context of Fear Shape Your Biomarker Strategy—Trust Agilex Biolabs to Define Your Success with a Context of Use!](https://www.agilexbiolabs.com/dont-let-a-context-of-fear-shape-your-biomarker-strategy-trust-agilex-biolabs-to-define-your-success-with-a-context-of-use/): By Dr. Kurt Sales, CSO - [LC-MS/MS Bioanalysis at Agilex Biolabs](https://www.agilexbiolabs.com/lc-ms-ms-bioanalysis-at-agilex-biolabs/): Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has been the preferred analytical method used in the pharmaceutical industry for fast, sensitive and quantitative bioanalysis of small molecule novel chemical entity drugs (NCEs) for a number of decades. Increasingly over the last 5-10 years it has also been used for the quantitative analysis of biopharmaceuticals, including peptides, proteins and more recently oligonucleotides. - [G’day UK! Agilex is Taking Part in a UK Roadshow Exploring a Turn-Key Solution to Clinical Trials in Australia](https://www.agilexbiolabs.com/gday-uk/): The Agilex team would like to invite you to join us for an exclusive delegation, where leading drug development experts will converge to unveil unparalleled opportunities for UK-based biotech innovators by revealing a turn-key solution for clinical trials in Australia. Discover how Australia offers the world’s fastest regulatory approval pathway into the clinic – guaranteeing swift access to critical Proof of Concept data. Couple this by gaining insights into the most generous R&D tax rebate system where eligible Biotechs can receive 43.5% cash back on R&D spend, empowering your investment dollars to stretch further. - [Unlocking the power of multiparameter flow cytometry in clinical trials – how many colors is optimal for a clinical study?](https://www.agilexbiolabs.com/unlocking-flow-colors-for-clinical-studies/): In an era where pharmaceuticals are becoming more targeted and complex, so have modern flow cytometers. With capabilities of analyzing greater than 40 parameters per tube simultaneously, modern flow cytometry has reshaped the discovery phase of many drug development and research programs by providing more data per tube, thereby speeding up the process of refining the key proteins associated with the drug’s function. Whilst this increase in capability has been welcomed by the Bioanalytical community, with many laboratories investing in new hardware, the increased complexity also presents several challenges around panel design, data analysis and interpretation, begging the question -  how many colors is optimal for a clinical study? - [Agilex Biolabs is Your Trusted Partner for Neuroscience Trials](https://www.agilexbiolabs.com/agilex-biolabs-is-your-trusted-partner-for-neuroscience-trials/): Our customers, Biotech’s and Pharma companies alike, leverage our expertise in immunology and bioanalysis to accelerate their neuroscience drug development programs. Being the largest bioanalytical laboratory with almost 30 years’ experience and global reach, Agilex Biolabs has become the trusted partner for neuroscience trials. - [Agilex Presents “Advancing Patient Centric Neurological Biomarker Detection by Characterizing Ultrasensitive Assays to Alleviate CSF Sample Burden” in San Antonio During WRIB](https://www.agilexbiolabs.com/agilex-presents-advancing-patient-centric-neurological-biomarker-detection-by-characterizing-ultrasensitive-assays-to-alleviate-csf-sample-burden-in-san-antonio-during-wrib/): Neurological disorders are a leading cause of morbidity and mortality  globally and represent a significant proportion of disease that has unmet clinical need. Due to this, many neurological drug discovery programs (DDP) now include assessment of relevant cerebral spinal fluid (CSF) biomarkers for patient screening, diagnosis, stratification, and drug product efficacy to improve patient outcomes. While CSF sampling provides valuable insights into the central nervous system, the invasiveness of the procedure presents a considerable challenge for patients, leading to discomfort and potential complications. This effect is compounded when the DDP requires longitudinal follow-up of patients for months or years. Recent advancements in ultra-sensitive assay platforms have enabled the detection of minute (≤ fg/mL) levels of neurological biomarkers in complex matrices. This offers a potential avenue for reducing the patient burden by using serum as the chosen assay matrix. - [Let Agilex put our Small Molecule Expertise to work for you when developing your Cannabis Studies and Programs](https://www.agilexbiolabs.com/let-agilex-put-our-small-molecule-expertise-to-work-for-you-when-developing-your-cannabis-studies-and-programs/): What makes Agilex perfectly suited for the testing of Medical Cannabis studies? - [Agilex: Accelerating Biopharma Innovation in Inflammatory Skin Disorders](https://www.agilexbiolabs.com/innovation-in-inflammatory-skin-disorders-dermatitis/): Addressing inflammatory skin disorders like atopic dermatitis (eczema) requires scientific expertise, a proven track record, and a deep understanding of these conditions' complexities. - [Meet the Agilex team: a Video Interview with Jason Valentine](https://www.agilexbiolabs.com/meet-the-agilex-team-jason-valentine/): My name is Jason Valentine. I'm the Founder and current Chief Operating Officer of Agilex Biolabs. - [Meet the Agilex team: a Video Interview with Kurt Sales, PhD](https://www.agilexbiolabs.com/meet-the-agilex-team-kurt-sales/): My name is Kurt Sales. I’m the Chief Scientific Officer at Agilex Biolabs. My role revolves around our scientific discussions, and being one of the first interactions with our clients (together with the business development team) to identify clients' needs, and scope out their projects. This early communication drives down the requirements to our operations teams. - [Formulating the Cancer Treatments of Tomorrow](https://www.agilexbiolabs.com/cancer-treatments-of-tomorrow/): Both the pace and varied methods by which medical clinicians utilize newer cancer treatments have been evolving exponentially for years now. For its part, Agilex Biolabs is proud to be able to make meaningful contributions to ongoing research and the promise of successful clinical trials. - [The Complex Role of Critical Reagents: The Agilex Approach](https://www.agilexbiolabs.com/role-of-critical-reagents/): Critical regents have earned the moniker “critical” with good reason. Functioning within this realm of drug development programs, critical reagents play a pivotal role in ensuring the accuracy and reliability of assays. - [An Introduction to Your New Senior Business Development Director, Mallory Jolly](https://www.agilexbiolabs.com/an-introduction-to-your-new-senior-business-development-director-mallory-jolly/): Bringing with her a wealth of experience and a passion for scientific breakthroughs, Mallory Jolly’s career trajectory reflects both personal dedication and a promising future of developing mutually rewarding international business relationships in the biopharma space. - [Comprehensive Bioanalytical Services from Agilex Biolabs in 2024](https://www.agilexbiolabs.com/comprehensive-bioanalytical-services-from-agilex-biolabs-in-2024/): Post-Covid, the field of bioanalysis has undergone significant industry-wide changes. These changes are unfolding more rapidly, catching some development companies off-guard. The ever-shifting landscape brings with it several implications for drug development in 2024. - [SGS Joins Forces with Agilex Biolabs, Marking Significant Step in Strengthening Global Footprint](https://www.agilexbiolabs.com/sgs-joins-forces-with-agilex-biolabs/): As Agilex Biolabs continues its global expansion and corporate evolution as part of the Healius network, Stephen McIntyre has been selected to take the position of Chief Executive Officer. - [Agilex: Engaging the Power of ddPCR forRobust, Rapid, and Precise Bioanalysis Results](https://www.agilexbiolabs.com/power-of-ddpcr/): Digital droplet polymerase chain reaction, or ddPCR, is an innovative molecular biology technique that holds tremendous promise for advancing various research and diagnostic endeavors. Imagine it as a powerful microscope for genetic material, enabling scientists to meticulously examine and quantify specific DNA or RNA sequences within a sample. - [Learn how Agilex Can Make Your PK Data SPARCL](https://www.agilexbiolabs.com/learn-how-agilex-can-make-your-pk-data-sparcl/): SPARCL stands for Spatial Proximity Analyte Reagent Complex Luminescence, which (as you can see) is quite a mouthful, so the industry has shortened it to SPARCL. SPARCL is a new variation on an immunoassay that functions as a in solution homogenous format due to its Horse Radish Peroxidase and Acridan labels. - [An Interview with Your Senior Business Development Manager, Amilia Wee](https://www.agilexbiolabs.com/an-interview-with-our-business-development-manager-amilia-wee/): It is with much enthusiasm that Agilex Biolabs introduces its newest Senior Development Manager, Amilia Wee. Amilia has been with Agilex for over two years, first as a proposal writer, and then as a Business Development Manager most recently. With such a wealth of knowledge and experience, we couldn't be more delighted to have Amilia stepping into her newest role as Senior Development Manager to provide informed and individualized value exactly where it is needed most. - [<strong>Agilex Biolabs: Providing World-class Immunoassay Services for Bioanalytical Research Worldwide</strong>](https://www.agilexbiolabs.com/agilex-biolabs-providing-world-class-immunoassay-services-for-bioanalytical-research-worldwide/): In the realm of bioanalytical research, immunoassays stand as a cornerstone technology, enabling the precise detection of biological drugs within complex matrices. Among the leaders in this field is Agilex, a laboratory that has set the global standard for immunoassay expertise. Let’s explore Agilex's exceptional capabilities and how they have earned their reputation as the go-to laboratory for immunoassays, not only in Australia but worldwide. - [An Interview with Our New Senior Business Development Director, Cameron Smith](https://www.agilexbiolabs.com/an-interview-with-our-new-senior-business-development-director-cameron-smith/): Agilex Biolabs is proud to introduce the West Coast of the United States to their new Senior Business Development Director, Cameron Smith. Cameron has over 14 years in the CRO industry, specializing in preclinical drug development (originally, he began with pharmacology). He began his scientific life as a bench top scientist but migrated to the commercial side of the CRO industry when joining Charles River Laboratories. Over the course of his 14 years in the industry, Cameron has supporting clients through Discovery, Proof of Concept, Lead Optimization and IND-enabling studies, most recently with organizations like Labcorp (formerly Covance) in Europe, Asia/Pac and North America. - [The Advantages of Polymerase Chain Reaction Testing in Pharmacokinetics at Agilex Biolabs](https://www.agilexbiolabs.com/the-advantages-of-polymerase-chain-reaction-testing-in-pharmacokinetics-at-agilex-biolabs/): Pharmacokinetics is a key component in a drug development program in enabling us to understand the absorption, distribution and metabolism of novel therapeutics. It is an aspect of the drug development industry that has changed drastically over the last decade. - [The Power of Flow Cytometry in Modern Pharmacokinetics from Agilex Biolabs](https://www.agilexbiolabs.com/flow-in-modern-pk/): In the ever-evolving landscape of pharmaceuticals, advancements in science have led to a shift in the types of therapeutic molecules being developed. Gone are the days of solely relying on small-molecule drugs and monoclonal antibodies. Instead, the emergence of mRNA therapies, antisense oligonucleotide treatments, and gene therapies has opened up new horizons for treating complex diseases. As we dive deeper into the realm of cell and gene therapy, pharmacokinetics (PK) and flow cytometry have become pivotal players in this transformative journey. ## Pages - [Off The Shelf Assays](https://www.agilexbiolabs.com/off-the-shelf-assays-8/) - [Off The Shelf Assays](https://www.agilexbiolabs.com/off-the-shelf-assays-7/) - [ThankYou – Agilex Biolabs](https://www.agilexbiolabs.com/form-thank-you/): ABOUT US Address Agilex Biolabs HQ 31 Dalgleish Street Thebarton SA 5031, Australia Agilex Brisbane Bioanalytical QIMR, 300 Herston Rd, Herston QLD 4006, Australia Phone Australia +61 8 8302 8787 USA +1 800 247 1909 China +86 21 8036 9483 South Korea +82 80 812 1255 Email Study Related Enquiries BD@https://www.agilexbiolabs.com General Enquiries info@https://www.agilexbiolabs.com Many Thanks for Your Request The Agilex Team will reach out to you within 24 hours - [Agilex Locations](https://www.agilexbiolabs.com/our-locations/): Agilex Adelaide is the company's headquarters and is the largest of our three facilities. It the FDA audited Centre of Excellence for Agilex's bioanalytical services and is home to almost 200 Agilex staff spanning three divisions, LC/MS, Immunoassay and Immunobiology. These three departments make up Australia's largest bioanalytical team. Our range of state-of-the-art instrumentation allows us to welcome any drug modality across a range of therapeutic indications. - [Quality](https://www.agilexbiolabs.com/quality/): Agilex Biolabs, our vision is to be a global leader in quality-driven bioanalytical services by embedding excellence into every process. Through our robust electronic Quality Management System, proactive  continuous improvement culture, and commitment to audit readiness, we strive to deliver reliable, compliant, and innovative solutions that exceed industry standards and customer expectations. We envision a future where quality is not just a goal, but a mindset - empowering our teams, enhancing our partnerships, and advancing life sciences with integrity and precision. - [Regulatory Compliance](https://www.agilexbiolabs.com/regulatory-compliance/): At Agilex Biolabs, regulatory compliance is more than a requirement, it's a cornerstone of our commitment to quality and integrity. Regulatory compliance is embedded in our tailored assay development, qualification, validation, and study analysis, ensuring alignment with international guidelines, industry standards, and your unique project requirements. - [Quality Assurance](https://www.agilexbiolabs.com/quality-assurance/): Our Quality Assurance team prides itself on the attraction and retention of high quality, appropriately-qualified, experienced industry experts with specialized expertise. Each auditor has a solid scientific background enabling an understanding of the technical complexities of bioanalysis. - [The Australian Advantage](https://www.agilexbiolabs.com/the-australian-advantage/): Australia provides one of the most compelling environments globally for clinical trials, combining high quality, rapid timelines, and cost-effectiveness with a world-class clinical and medical sector. Agilex Biolabs is the perfect partner for Bio Pharma services in Australia. - [Contact Us – Agilex Biolabs](https://www.agilexbiolabs.com/contact-us-now/): %3Cscript%3Ewindow.enableEventObserver%3Dtrue%3C%2Fscript%3E%0A%3Cscript%20src%3D%22https%3A%2F%2Fcdn.jotfor.ms%2Fstatic%2Fprototype.forms.js%3Fv%3D3.3.62801%22%20type%3D%22text%2Fjavascript%22%3E%3C%2Fscript%3E%0A%3Cscript%20src%3D%22https%3A%2F%2Fcdn.jotfor.ms%2Fstatic%2Fjotform.forms.js%3Fv%3D3.3.62801%22%20type%3D%22text%2Fjavascript%22%3E%3C%2Fscript%3E%0A%3Cscript%20src%3D%22https%3A%2F%2Fcdn.jotfor.ms%2Fjs%2Fpunycode-1.4.1.min.js%3Fv%3D3.3.62801%22%20type%3D%22text%2Fjavascript%22%20defer%3E%3C%2Fscript%3E%0A%3Cscript%20src%3D%22https%3A%2F%2Fcdn.jotfor.ms%2Fs%2Fumd%2Fec39bbf2214%2Ffor-form-encryption.js%3Fv%3D3.3.62801%22%20type%3D%22text%2Fjavascript%22%3E%3C%2Fscript%3E%0A%3Cscript%20src%3D%22https%3A%2F%2Fcdn.jotfor.ms%2Fs%2Fumd%2Fec39bbf2214%2Ffor-form-branding-footer.js%3Fv%3D3.3.62801%22%20type%3D%22text%2Fjavascript%22%20defer%3E%3C%2Fscript%3E%0A%3Cscript%20src%3D%22https%3A%2F%2Fcdn.jotfor.ms%2Fjs%2Fvendor%2Fsmoothscroll.min.js%3Fv%3D3.3.62801%22%20type%3D%22text%2Fjavascript%22%3E%3C%2Fscript%3E%0A%3Cscript%20src%3D%22https%3A%2F%2Fcdn.jotfor.ms%2Fjs%2FerrorNavigation.js%3Fv%3D3.3.62801%22%20type%3D%22text%2Fjavascript%22%3E%3C%2Fscript%3E%0A%3Cscript%20type%3D%22text%2Fjavascript%22%3E%09JotForm.newDefaultTheme%20%3D%20true%3B%0A%09JotForm.extendsNewTheme%20%3D%20false%3B%0A%09JotForm.singleProduct%20%3D%20false%3B%0A%09JotForm.newPaymentUIForNewCreatedForms%20%3D%20true%3B%0A%09JotForm.texts%20%3D%20%7B%22confirmEmail%22%3A%22E-mail%20does%20not%20match%22%2C%22pleaseWait%22%3A%22Please%20wait...%22%2C%22validateEmail%22%3A%22You%20need%20to%20validate%20this%20e-mail%22%2C%22confirmClearForm%22%3A%22Are%20you%20sure%20you%20want%20to%20clear%20the%20form%22%2C%22lessThan%22%3A%22Your%20score%20should%20be%20less%20than%20or%20equal%20to%22%2C%22incompleteFields%22%3A%22There%20are%20incomplete%20required%20fields.%20Please%20complete%20them.%22%2C%22required%22%3A%22This%20field%20is%20required.%22%2C%22requireOne%22%3A%22At%20least%20one%20field%20required.%22%2C%22requireEveryRow%22%3A%22Every%20row%20is%20required.%22%2C%22requireEveryCell%22%3A%22Every%20cell%20is%20required.%22%2C%22email%22%3A%22Enter%20a%20valid%20e-mail%20address%22%2C%22alphabetic%22%3A%22This%20field%20can%20only%20contain%20letters%22%2C%22numeric%22%3A%22This%20field%20can%20only%20contain%20numeric%20values%22%2C%22alphanumeric%22%3A%22This%20field%20can%20only%20contain%20letters%20and%20numbers.%22%2C%22cyrillic%22%3A%22This%20field%20can%20only%20contain%20cyrillic%20characters%22%2C%22url%22%3A%22This%20field%20can%20only%20contain%20a%20valid%20URL%22%2C%22currency%22%3A%22This%20field%20can%20only%20contain%20currency%20values.%22%2C%22fillMask%22%3A%22Field%20value%20must%20fill%20mask.%22%2C%22uploadExtensions%22%3A%22You%20can%20only%20upload%20following%20files%3A%22%2C%22noUploadExtensions%22%3A%22File%20has%20no%20extension%20file%20type%20%28e.g.%20.txt%2C%20.png%2C%20.jpeg%29%22%2C%22uploadFilesize%22%3A%22File%20size%20cannot%20be%20bigger%20than%3A%22%2C%22uploadFilesizemin%22%3A%22File%20size%20cannot%20be%20smaller%20than%3A%22%2C%22gradingScoreError%22%3A%22Score%20total%20should%20only%20be%20less%20than%20or%20equal%20to%22%2C%22inputCarretErrorA%22%3A%22Input%20should%20not%20be%20less%20than%20the%20minimum%20value%3A%22%2C%22inputCarretErrorB%22%3A%22Input%20should%20not%20be%20greater%20than%20the%20maximum%20value%3A%22%2C%22maxDigitsError%22%3A%22The%20maximum%20digits%20allowed%20is%22%2C%22minCharactersError%22%3A%22The%20number%20of%20characters%20should%20not%20be%20less%20than%20the%20minimum%20value%3A%22%2C%22maxCharactersError%22%3A%22The%20number%20of%20characters%20should%20not%20be%20more%20than%20the%20maximum%20value%3A%22%2C%22freeEmailError%22%3A%22Free%20email%20accounts%20are%20not%20allowed%22%2C%22minSelectionsError%22%3A%22The%20minimum%20required%20number%20of%20selections%20is%20%22%2C%22maxSelectionsError%22%3A%22The%20maximum%20number%20of%20selections%20allowed%20is%20%22%2C%22pastDatesDisallowed%22%3A%22Date%20must%20not%20be%20in%20the%20past.%22%2C%22dateLimited%22%3A%22This%20date%20is%20unavailable.%22%2C%22dateInvalid%22%3A%22This%20date%20is%20not%20valid.%20The%20date%20format%20is%20%7Bformat%7D%22%2C%22dateInvalidSeparate%22%3A%22This%20date%20is%20not%20valid.%20Enter%20a%20valid%20%7Belement%7D.%22%2C%22ageVerificationError%22%3A%22You%20must%20be%20older%20than%20%7BminAge%7D%20years%20old%20to%20submit%20this%20form.%22%2C%22multipleFileUploads_typeError%22%3A%22%7Bfile%7D%20has%20invalid%20extension.%20Only%20%7Bextensions%7D%20are%20allowed.%22%2C%22multipleFileUploads_sizeError%22%3A%22%7Bfile%7D%20is%20too%20large%2C%20maximum%20file%20size%20is%20%7BsizeLimit%7D.%22%2C%22multipleFileUploads_minSizeError%22%3A%22%7Bfile%7D%20is%20too%20small%2C%20minimum%20file%20size%20is%20%7BminSizeLimit%7D.%22%2C%22multipleFileUploads_emptyError%22%3A%22%7Bfile%7D%20is%20empty%2C%20please%20select%20files%20again%20without%20it.%22%2C%22multipleFileUploads_uploadFailed%22%3A%22File%20upload%20failed%2C%20please%20remove%20it%20and%20upload%20the%20file%20again.%22%2C%22multipleFileUploads_onLeave%22%3A%22The%20files%20are%20being%20uploaded%2C%20if%20you%20leave%20now%20the%20upload%20will%20be%20cancelled.%22%2C%22multipleFileUploads_fileLimitError%22%3A%22Only%20%7BfileLimit%7D%20file%20uploads%20allowed.%22%2C%22dragAndDropFilesHere_infoMessage%22%3A%22Drag%20and%20drop%20files%20here%22%2C%22chooseAFile_infoMessage%22%3A%22Choose%20a%20file%22%2C%22maxFileSize_infoMessage%22%3A%22Max.%20file%20size%22%2C%22generalError%22%3A%22There%20are%20errors%20on%20the%20form.%20Please%20fix%20them%20before%20continuing.%22%2C%22generalPageError%22%3A%22There%20are%20errors%20on%20this%20page.%20Please%20fix%20them%20before%20continuing.%22%2C%22wordLimitError%22%3A%22Too%20many%20words.%20The%20limit%20is%22%2C%22wordMinLimitError%22%3A%22Too%20few%20words.%20%20The%20minimum%20is%22%2C%22characterLimitError%22%3A%22Too%20many%20Characters.%20%20The%20limit%20is%22%2C%22characterMinLimitError%22%3A%22Too%20few%20characters.%20The%20minimum%20is%22%2C%22ccInvalidNumber%22%3A%22Credit%20Card%20Number%20is%20invalid.%22%2C%22ccInvalidCVC%22%3A%22CVC%20number%20is%20invalid.%22%2C%22ccInvalidExpireDate%22%3A%22Expire%20date%20is%20invalid.%22%2C%22ccInvalidExpireMonth%22%3A%22Expiration%20month%20is%20invalid.%22%2C%22ccInvalidExpireYear%22%3A%22Expiration%20year%20is%20invalid.%22%2C%22ccMissingDetails%22%3A%22Please%20fill%20up%20the%20credit%20card%20details.%22%2C%22ccMissingProduct%22%3A%22Please%20select%20at%20least%20one%20product.%22%2C%22ccMissingDonation%22%3A%22Please%20enter%20numeric%20values%20for%20donation%20amount.%22%2C%22disallowDecimals%22%3A%22Please%20enter%20a%20whole%20number.%22%2C%22restrictedDomain%22%3A%22This%20domain%20is%20not%20allowed%22%2C%22ccDonationMinLimitError%22%3A%22Minimum%20amount%20is%20%7BminAmount%7D%20%7Bcurrency%7D%22%2C%22requiredLegend%22%3A%22All%20fields%20marked%20with%20%2A%20are%20required%20and%20must%20be%20filled.%22%2C%22geoPermissionTitle%22%3A%22Permission%20Denied%22%2C%22geoPermissionDesc%22%3A%22Check%20your%20browser%27s%20privacy%20settings.%22%2C%22geoNotAvailableTitle%22%3A%22Position%20Unavailable%22%2C%22geoNotAvailableDesc%22%3A%22Location%20provider%20not%20available.%20Please%20enter%20the%20address%20manually.%22%2C%22geoTimeoutTitle%22%3A%22Timeout%22%2C%22geoTimeoutDesc%22%3A%22Please%20check%20your%20internet%20connection%20and%20try%20again.%22%2C%22selectedTime%22%3A%22Selected%20Time%22%2C%22formerSelectedTime%22%3A%22Former%20Time%22%2C%22cancelAppointment%22%3A%22Cancel%20Appointment%22%2C%22cancelSelection%22%3A%22Cancel%20Selection%22%2C%22noSlotsAvailable%22%3A%22No%20slots%20available%22%2C%22slotUnavailable%22%3A%22%7Btime%7D%20on%20%7Bdate%7D%20has%20been%20selected%20is%20unavailable.%20Please%20select%20another%20slot.%22%2C%22multipleError%22%3A%22There%20are%20%7Bcount%7D%20errors%20on%20this%20page.%20Please%20correct%20them%20before%20moving%20on.%22%2C%22oneError%22%3A%22There%20is%20%7Bcount%7D%20error%20on%20this%20page.%20Please%20correct%20it%20before%20moving%20on.%22%2C%22doneMessage%22%3A%22Well%20done%21%20All%20errors%20are%20fixed.%22%2C%22invalidTime%22%3A%22Enter%20a%20valid%20time%22%2C%22doneButton%22%3A%22Done%22%2C%22reviewSubmitText%22%3A%22Review%20and%20Submit%22%2C%22nextButtonText%22%3A%22Next%22%2C%22prevButtonText%22%3A%22Previous%22%2C%22seeErrorsButton%22%3A%22See%20Errors%22%2C%22notEnoughStock%22%3A%22Not%20enough%20stock%20for%20the%20current%20selection%22%2C%22notEnoughStock_remainedItems%22%3A%22Not%20enough%20stock%20for%20the%20current%20selection%20%28%7Bcount%7D%20items%20left%29%22%2C%22soldOut%22%3A%22Sold%20Out%22%2C%22justSoldOut%22%3A%22Just%20Sold%20Out%22%2C%22selectionSoldOut%22%3A%22Selection%20Sold%20Out%22%2C%22subProductItemsLeft%22%3A%22%28%7Bcount%7D%20items%20left%29%22%2C%22startButtonText%22%3A%22START%22%2C%22submitButtonText%22%3A%22Submit%22%2C%22submissionLimit%22%3A%22Sorry%21%20Only%20one%20entry%20is%20allowed.%20%3Cbr%3E%20Multiple%20submissions%20are%20disabled%20for%20this%20form.%22%2C%22reviewBackText%22%3A%22Back%20to%20Form%22%2C%22seeAllText%22%3A%22See%20All%22%2C%22progressMiddleText%22%3A%22of%22%2C%22fieldError%22%3A%22field%20has%20an%20error.%22%2C%22error%22%3A%22Error%22%7D%3B%0A%09JotForm.newPaymentUI%20%3D%20true%3B%0A%09JotForm.originalLanguage%20%3D%20%22en%22%3B%0A%09JotForm.isFormViewTrackingAllowed%20%3D%20true%3B%0A%09JotForm.replaceTagTest%20%3D%20true%3B%0A%09JotForm.uploadServerURL%20%3D%20%22https%3A%2F%2Fupload.jotform.com%2Fupload%22%3B%0A%09JotForm.clearFieldOnHide%3D%22disable%22%3B%0A%09JotForm.submitError%3D%22jumpToFirstError%22%3B%0A%09JotForm.encryptionProtocol%20%3D%20%22JF-CSE-V2%22%3B%0A%09window.addEventListener%28%27DOMContentLoaded%27%2Cfunction%28%29%7Bwindow.brandingFooter.init%28%7B%22formID%22%3A251316737507054%2C%22campaign%22%3A%22powered_by_jotform_le%22%2C%22isCardForm%22%3Afalse%2C%22isLegacyForm%22%3Atrue%2C%22formLanguage%22%3A%22en%22%7D%29%7D%29%3B%09JotForm.isFullSource%20%3D%20true%3B%0A%0A%20%20%20%20%20%20try%7B%0A%20%20%20%20%20%20%20%20function%20isTrackingProhibited%28%29%20%7B%0A%20%20%20%20%20%20try%20%7B%0A%20%20%20%20%20%20%20%20var%20isEUDomain%20%3D%20%2F%28%3F%3Aeu.jotform%29%7C%28%3F%3Ajotformeu.com%29%2F.test%28window.location.host%29%3B%0A%20%20%20%20%20%20%20%20var%20isHipaaDomain%20%3D%20%2F%28%3F%3Ahipaa.jotform%29%2F.test%28window.location.host%29%3B%0A%20%20%20%20%20%20%20%20var%20isProhibitedParameterExists%20%3D%20%2F%28%3F%3AwfTaskID%7CPCI_preSubmitRequest%7CwfTaskType%29%2F.test%28window.location.search%29%3B%0A%20%20%20%20%20%20%20%20var%20isEditMode%20%3D%20JotForm.isEditMode%28%29%3B%0A%20%20%20%20%20%20%20%20var%20isTrackingProhibited%20%3D%20isEUDomain%20%7C%7C%20isHipaaDomain%20%7C%7C%20isProhibitedParameterExists%20%7C%7C%20isEditMode%3B%0A%20%20%20%20%20%20%20%20return%20isTrackingProhibited%3B%0A%20%20%20%20%20%20%7D%20catch%20%28e%29%20%7B%0A%20%20%20%20%20%20%20%20console.log%28e%29%3B%0A%20%20%20%20%20%20%20%20return%20true%3B%0A%20%20%20%20%20%20%7D%0A%20%20%20%20%7D%0A%20%20%20%20%20%20%20%20if%20%28%21isTrackingProhibited%28%29%29%20%7B%0A%20%20%20%20%20%20%20%20%20%20var%20sesApiUrl%20%3D%20%2Fjotform.pro%2F.test%28window.location.host%29%20%3F%20%27%2FAPI%27%20%3A%20%27https%3A%2F%2Fapi.jotform.com%27%3B%0A%20%20%20%20%20%20%20%20%20%20function%20sendOpenId%28uuid%2C%20eventType%29%20%7B%0A%20%20%20%20%20%20%20%20%20%20%20%20navigator.sendBeacon%28sesApiUrl%20%2B%20%27%2Fform%2F%27%20%2B%20251316737507054%20%2B%20%27%2Fevent%2F%27%20%2B%20uuid%20%2B%20%27%2F%27%20%2B%20eventType%2C%20%7B%7D%29%3B%0A%20%20%20%20%20%20%20%20%20%20%7D%0A%20%20%20%20%20%20%20%20%20%20var%20formOpenId%20%3D%20%27%27%3B%0A%20%20%20%20%20%20%20%20%20%20if%20%28window.crypto%29%20%7B%0A%20%20%20%20%20%20%20%20%20%20%20%20formOpenId%20%3D%20window.crypto.getRandomValues%28new%20BigUint64Array%281%29%29.toString%28%29%3B%0A%20%20%20%20%20%20%20%20%20%20%7D%20else%20%7B%0A%20%20%20%20%20%20%20%20%20%20%20%20formOpenId%20%3D%20%28Math.random%28%29%20%2A%2016%29.toString%2816%29.slice%282%29%3B%0A%20%20%20%20%20%20%20%20%20%20%7D%0A%20%20%20%20%20%20%20%20%20%20sendOpenId%20%3D%20sendOpenId.bind%28this%2C%20formOpenId%29%3B%0A%20%20%20%20%20%20%20%20%20%20function%20sendOpenIdOnSubmit%28%29%20%7B%0A%20%20%20%20%20%20%20%20%20%20%20%20var%20currentForm%20%3D%20%24%28%27251316737507054%27%29%3B%0A%20%20%20%20%20%20%20%20%20%20%20%20currentForm.addEventListener%28%27submit%27%2C%20function%28%29%20%7B%20sendOpenId%28%27clientSubmitClick_V5%27%29%3B%20%7D%29%3B%0A%20%20%20%20%20%20%20%20%20%20%20%20var%20openIdInput%20%3D%20currentForm.querySelector%28%27%5Bname%3D%22formOpenId_V5%22%5D%27%29%3B%0A%20%20%20%20%20%20%20%20%20%20%20%20if%20%28%21openIdInput%29%20%7B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20openIdInput%20%3D%20document.createElement%28%27input%27%29%3B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20openIdInput.setAttribute%28%27type%27%2C%20%27hidden%27%29%3B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20openIdInput.setAttribute%28%27name%27%2C%20%27formOpenId_V5%27%29%3B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20currentForm.appendChild%28openIdInput%29%3B%0A%20%20%20%20%20%20%20%20%20%20%20%20%7D%0A%20%20%20%20%20%20%20%20%20%20%20%20openIdInput.value%20%3D%20formOpenId%3B%0A%20%20%20%20%20%20%20%20%20%20%7D%0A%20%20%20%20%20%20%20%20%20%20sendOpenId%28%27clientFormView_V5%27%29%3B%0A%20%20%20%20%20%20%20%20%20%20if%20%28document.readyState%20%3D%3D%20%27complete%27%20%7C%7C%20%28this.jsForm%20%26%26%20%28document.readyState%20%3D%3D%3D%20undefined%20%7C%7C%20document.readyState%20%3D%3D%3D%20%27interactive%27%29%29%29%20%7B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20sendOpenIdOnSubmit%28%29%3B%0A%20%20%20%20%20%20%20%20%20%20%7D%20else%20%7B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20document.ready%28sendOpenIdOnSubmit%29%3B%0A%20%20%20%20%20%20%20%20%20%20%7D%0A%20%20%20%20%20%20%20%20%7D%0A%20%20%20%20%20%20%7D%20catch%28openIdBlockError%29%20%7B%0A%20%20%20%20%20%20%20%20console.log%28openIdBlockError%29%3B%0A%20%20%20%20%20%20%7D%0A%20%20%20%20%0A%09JotForm.init%28function%28%29%7B%0A%09%2F%2AINIT-START%2A%2F%0A%20%20%20%20%20%20JotForm.alterTexts%28%7B%22ageVerificationError%22%3A%22You%20must%20be%20older%20than%20%7BminAge%7D%20years%20old%20to%20submit%20this%20form.%22%2C%22alphabetic%22%3A%22This%20field%20can%20only%20contain%20letters%22%2C%22alphanumeric%22%3A%22This%20field%20can%20only%20contain%20letters%20and%20numbers.%22%2C%22cancelAppointment%22%3A%22Cancel%20Appointment%22%2C%22cancelSelection%22%3A%22Cancel%20Selection%22%2C%22ccDonationMinLimitError%22%3A%22Minimum%20amount%20is%20%7BminAmount%7D%20%7Bcurrency%7D%22%2C%22ccInvalidCVC%22%3A%22CVC%20number%20is%20invalid.%22%2C%22ccInvalidExpireDate%22%3A%22Expire%20date%20is%20invalid.%22%2C%22ccInvalidExpireMonth%22%3A%22Expiration%20month%20is%20invalid.%22%2C%22ccInvalidExpireYear%22%3A%22Expiration%20year%20is%20invalid.%22%2C%22ccInvalidNumber%22%3A%22Credit%20Card%20Number%20is%20invalid.%22%2C%22ccMissingDetails%22%3A%22Please%20fill%20up%20the%20credit%20card%20details.%22%2C%22ccMissingDonation%22%3A%22Please%20enter%20numeric%20values%20for%20donation%20amount.%22%2C%22ccMissingProduct%22%3A%22Please%20select%20at%20least%20one%20product.%22%2C%22characterLimitError%22%3A%22Too%20many%20Characters.%20%20The%20limit%20is%22%2C%22characterMinLimitError%22%3A%22Too%20few%20characters.%20The%20minimum%20is%22%2C%22chooseAFile_infoMessage%22%3A%22Choose%20a%20file%22%2C%22confirmClearForm%22%3A%22Are%20you%20sure%20you%20want%20to%20clear%20the%20form%22%2C%22confirmEmail%22%3A%22E-mail%20does%20not%20match%22%2C%22currency%22%3A%22This%20field%20can%20only%20contain%20currency%20values.%22%2C%22cyrillic%22%3A%22This%20field%20can%20only%20contain%20cyrillic%20characters%22%2C%22dateInvalid%22%3A%22This%20date%20is%20not%20valid.%20The%20date%20format%20is%20%7Bformat%7D%22%2C%22dateInvalidSeparate%22%3A%22This%20date%20is%20not%20valid.%20Enter%20a%20valid%20%7Belement%7D.%22%2C%22dateLimited%22%3A%22This%20date%20is%20unavailable.%22%2C%22disallowDecimals%22%3A%22Please%20enter%20a%20whole%20number.%22%2C%22doneButton%22%3A%22Done%22%2C%22doneMessage%22%3A%22Well%20done%21%20All%20errors%20are%20fixed.%22%2C%22dragAndDropFilesHere_infoMessage%22%3A%22Drag%20and%20drop%20files%20here%22%2C%22email%22%3A%22Enter%20a%20valid%20e-mail%20address%22%2C%22error%22%3A%22Error%22%2C%22fieldError%22%3A%22field%20has%20an%20error.%22%2C%22fillMask%22%3A%22Field%20value%20must%20fill%20mask.%22%2C%22formerSelectedTime%22%3A%22Former%20Time%22%2C%22freeEmailError%22%3A%22Free%20email%20accounts%20are%20not%20allowed%22%2C%22generalError%22%3A%22There%20are%20errors%20on%20the%20form.%20Please%20fix%20them%20before%20continuing.%22%2C%22generalPageError%22%3A%22There%20are%20errors%20on%20this%20page.%20Please%20fix%20them%20before%20continuing.%22%2C%22geoNotAvailableDesc%22%3A%22Location%20provider%20not%20available.%20Please%20enter%20the%20address%20manually.%22%2C%22geoNotAvailableTitle%22%3A%22Position%20Unavailable%22%2C%22geoPermissionDesc%22%3A%22Check%20your%20browser%27s%20privacy%20settings.%22%2C%22geoPermissionTitle%22%3A%22Permission%20Denied%22%2C%22geoTimeoutDesc%22%3A%22Please%20check%20your%20internet%20connection%20and%20try%20again.%22%2C%22geoTimeoutTitle%22%3A%22Timeout%22%2C%22gradingScoreError%22%3A%22Score%20total%20should%20only%20be%20less%20than%20or%20equal%20to%22%2C%22incompleteFields%22%3A%22There%20are%20incomplete%20required%20fields.%20Please%20complete%20them.%22%2C%22inputCarretErrorA%22%3A%22Input%20should%20not%20be%20less%20than%20the%20minimum%20value%3A%22%2C%22inputCarretErrorB%22%3A%22Input%20should%20not%20be%20greater%20than%20the%20maximum%20value%3A%22%2C%22invalidTime%22%3A%22Enter%20a%20valid%20time%22%2C%22justSoldOut%22%3A%22Just%20Sold%20Out%22%2C%22lessThan%22%3A%22Your%20score%20should%20be%20less%20than%20or%20equal%20to%22%2C%22maxCharactersError%22%3A%22The%20number%20of%20characters%20should%20not%20be%20more%20than%20the%20maximum%20value%3A%22%2C%22maxDigitsError%22%3A%22The%20maximum%20digits%20allowed%20is%22%2C%22maxFileSize_infoMessage%22%3A%22Max.%20file%20size%22%2C%22maxSelectionsError%22%3A%22The%20maximum%20number%20of%20selections%20allowed%20is%20%22%2C%22minCharactersError%22%3A%22The%20number%20of%20characters%20should%20not%20be%20less%20than%20the%20minimum%20value%3A%22%2C%22minSelectionsError%22%3A%22The%20minimum%20required%20number%20of%20selections%20is%20%22%2C%22multipleError%22%3A%22There%20are%20%7Bcount%7D%20errors%20on%20this%20page.%20Please%20correct%20them%20before%20moving%20on.%22%2C%22multipleFileUploads_emptyError%22%3A%22%7Bfile%7D%20is%20empty%2C%20please%20select%20files%20again%20without%20it.%22%2C%22multipleFileUploads_fileLimitError%22%3A%22Only%20%7BfileLimit%7D%20file%20uploads%20allowed.%22%2C%22multipleFileUploads_minSizeError%22%3A%22%7Bfile%7D%20is%20too%20small%2C%20minimum%20file%20size%20is%20%7BminSizeLimit%7D.%22%2C%22multipleFileUploads_onLeave%22%3A%22The%20files%20are%20being%20uploaded%2C%20if%20you%20leave%20now%20the%20upload%20will%20be%20cancelled.%22%2C%22multipleFileUploads_sizeError%22%3A%22%7Bfile%7D%20is%20too%20large%2C%20maximum%20file%20size%20is%20%7BsizeLimit%7D.%22%2C%22multipleFileUploads_typeError%22%3A%22%7Bfile%7D%20has%20invalid%20extension.%20Only%20%7Bextensions%7D%20are%20allowed.%22%2C%22multipleFileUploads_uploadFailed%22%3A%22File%20upload%20failed%2C%20please%20remove%20it%20and%20upload%20the%20file%20again.%22%2C%22nextButtonText%22%3A%22Next%22%2C%22noSlotsAvailable%22%3A%22No%20slots%20available%22%2C%22notEnoughStock%22%3A%22Not%20enough%20stock%20for%20the%20current%20selection%22%2C%22notEnoughStock_remainedItems%22%3A%22Not%20enough%20stock%20for%20the%20current%20selection%20%28%7Bcount%7D%20items%20left%29%22%2C%22noUploadExtensions%22%3A%22File%20has%20no%20extension%20file%20type%20%28e.g.%20.txt%2C%20.png%2C%20.jpeg%29%22%2C%22numeric%22%3A%22This%20field%20can%20only%20contain%20numeric%20values%22%2C%22oneError%22%3A%22There%20is%20%7Bcount%7D%20error%20on%20this%20page.%20Please%20correct%20it%20before%20moving%20on.%22%2C%22pastDatesDisallowed%22%3A%22Date%20must%20not%20be%20in%20the%20past.%22%2C%22pleaseWait%22%3A%22Please%20wait...%22%2C%22prevButtonText%22%3A%22Previous%22%2C%22progressMiddleText%22%3A%22of%22%2C%22required%22%3A%22This%20field%20is%20required.%22%2C%22requiredLegend%22%3A%22All%20fields%20marked%20with%20%2A%20are%20required%20and%20must%20be%20filled.%22%2C%22requireEveryCell%22%3A%22Every%20cell%20is%20required.%22%2C%22requireEveryRow%22%3A%22Every%20row%20is%20required.%22%2C%22requireOne%22%3A%22At%20least%20one%20field%20required.%22%2C%22restrictedDomain%22%3A%22This%20domain%20is%20not%20allowed%22%2C%22reviewBackText%22%3A%22Back%20to%20Form%22%2C%22reviewSubmitText%22%3A%22Review%20and%20Submit%22%2C%22seeAllText%22%3A%22See%20All%22%2C%22seeErrorsButton%22%3A%22See%20Errors%22%2C%22selectedTime%22%3A%22Selected%20Time%22%2C%22selectionSoldOut%22%3A%22Selection%20Sold%20Out%22%2C%22slotUnavailable%22%3A%22%7Btime%7D%20on%20%7Bdate%7D%20has%20been%20selected%20is%20unavailable.%20Please%20select%20another%20slot.%22%2C%22soldOut%22%3A%22Sold%20Out%22%2C%22startButtonText%22%3A%22START%22%2C%22submissionLimit%22%3A%22Sorry%21%20Only%20one%20entry%20is%20allowed.%20%26lt%3Bbr%26gt%3B%20Multiple%20submissions%20are%20disabled%20for%20this%20form.%22%2C%22submitButtonText%22%3A%22Submit%22%2C%22subProductItemsLeft%22%3A%22%28%7Bcount%7D%20items%20left%29%22%2C%22uploadExtensions%22%3A%22You%20can%20only%20upload%20following%20files%3A%22%2C%22uploadFilesize%22%3A%22File%20size%20cannot%20be%20bigger%20than%3A%22%2C%22uploadFilesizemin%22%3A%22File%20size%20cannot%20be%20smaller%20than%3A%22%2C%22url%22%3A%22This%20field%20can%20only%20contain%20a%20valid%20URL%22%2C%22validateEmail%22%3A%22You%20need%20to%20validate%20this%20e-mail%22%2C%22wordLimitError%22%3A%22Too%20many%20words.%20The%20limit%20is%22%2C%22wordMinLimitError%22%3A%22Too%20few%20words.%20%20The%20minimum%20is%22%7D%29%3B%0A%09%2F%2AINIT-END%2A%2F%0A%09%7D%29%3B%0A%0A%20%20%20setTimeout%28function%28%29%20%7B%0AJotForm.paymentExtrasOnTheFly%28%5Bnull%2Cnull%2C%7B%22name%22%3A%22submit2%22%2C%22qid%22%3A%222%22%2C%22text%22%3A%22Submit%22%2C%22type%22%3A%22control_button%22%7D%2C%7B%22description%22%3A%22%22%2C%22name%22%3A%22name%22%2C%22qid%22%3A%223%22%2C%22text%22%3A%22Name%22%2C%22type%22%3A%22control_fullname%22%7D%2C%7B%22description%22%3A%22%22%2C%22name%22%3A%22email%22%2C%22qid%22%3A%224%22%2C%22subLabel%22%3A%22example%40example.com%22%2C%22text%22%3A%22Email%22%2C%22type%22%3A%22control_email%22%7D%5D%29%3B%7D%2C%2020%29%3B%20%0A%3C%2Fscript%3E%0A%3Clink%20type%3D%22text%2Fcss%22%20rel%3D%22stylesheet%22%20href%3D%22https%3A%2F%2Fcdn.jotfor.ms%2Fstylebuilder%2Fstatic%2Fform-common.css%3Fv%3D421d4e0%0A%22%2F%3E%0A%3Cstyle%20type%3D%22text%2Fcss%22%3E%40media%20print%7B%2A%7B-webkit-print-color-adjust%3A%20exact%20%21important%3Bcolor-adjust%3A%20exact%20%21important%3B%7D.form-section%7Bdisplay%3Ainline%21important%7D.form-pagebreak%7Bdisplay%3Anone%21important%7D.form-section-closed%7Bheight%3Aauto%21important%7D.page-section%7Bposition%3Ainitial%21important%7D%7D%3C%2Fstyle%3E%0A%3Clink%20type%3D%22text%2Fcss%22%20rel%3D%22stylesheet%22%20href%3D%22https%3A%2F%2Fcdn.jotfor.ms%2Fthemes%2FCSS%2F5e6b428acc8c4e222d1beb91.css%3Fv%3D3.3.62801%22%2F%3E%0A%3Clink%20type%3D%22text%2Fcss%22%20rel%3D%22stylesheet%22%20href%3D%22https%3A%2F%2Fcdn.jotfor.ms%2Fcss%2Fstyles%2Fpayment%2Fpayment_styles.css%3F3.3.62801%22%20%2F%3E%0A%3Clink%20type%3D%22text%2Fcss%22%20rel%3D%22stylesheet%22%20href%3D%22https%3A%2F%2Fcdn.jotfor.ms%2Fcss%2Fstyles%2Fpayment%2Fpayment_feature.css%3F3.3.62801%22%20%2F%3E%0A%3Cform%20class%3D%22jotform-form%22%20onsubmit%3D%22return%20typeof%20testSubmitFunction%20%21%3D%3D%20%27undefined%27%20%26%26%20testSubmitFunction%28%29%3B%22%20action%3D%22https%3A%2F%2Fsubmit.jotform.com%2Fsubmit%2F251316737507054%22%20method%3D%22post%22%20name%3D%22form_251316737507054%22%20id%3D%22251316737507054%22%20accept-charset%3D%22utf-8%22%20autocomplete%3D%22on%22%3E%3Cinput%20type%3D%22hidden%22%20name%3D%22formID%22%20value%3D%22251316737507054%22%20%2F%3E%3Cinput%20type%3D%22hidden%22%20id%3D%22JWTContainer%22%20value%3D%22%22%20%2F%3E%3Cinput%20type%3D%22hidden%22%20id%3D%22cardinalOrderNumber%22%20value%3D%22%22%20%2F%3E%3Cinput%20type%3D%22hidden%22%20id%3D%22jsExecutionTracker%22%20name%3D%22jsExecutionTracker%22%20value%3D%22build-date-1747091098301%22%20%2F%3E%3Cinput%20type%3D%22hidden%22%20id%3D%22submitSource%22%20name%3D%22submitSource%22%20value%3D%22unknown%22%20%2F%3E%3Cinput%20type%3D%22hidden%22%20id%3D%22buildDate%22%20name%3D%22buildDate%22%20value%3D%221747091098301%22%20%2F%3E%3Cinput%20type%3D%22hidden%22%20name%3D%22uploadServerUrl%22%20value%3D%22https%3A%2F%2Fupload.jotform.com%2Fupload%22%20%2F%3E%3Cinput%20type%3D%22hidden%22%20name%3D%22eventObserver%22%20value%3D%221%22%20%2F%3E%0A%20%20%3Cdiv%20role%3D%22main%22%20class%3D%22form-all%22%3E%0A%20%20%20%20%3Cul%20class%3D%22form-section%20page-section%22%20role%3D%22presentation%22%3E%0A%20%20%20%20%20%20%3Cli%20class%3D%22form-line%22%20data-type%3D%22control_fullname%22%20id%3D%22id_3%22%3E%3Clabel%20class%3D%22form-label%20form-label-top%20form-label-auto%22%20id%3D%22label_3%22%20for%3D%22first_3%22%20aria-hidden%3D%22false%22%3E%20Name%20%3C%2Flabel%3E%0A%20%20%20%20%20%20%20%20%3Cdiv%20id%3D%22cid_3%22%20class%3D%22form-input-wide%22%20data-layout%3D%22full%22%3E%0A%20%20%20%20%20%20%20%20%20%20%3Cdiv%20data-wrapper-react%3D%22true%22%3E%3Cspan%20class%3D%22form-sub-label-container%22%20style%3D%22vertical-align%3Atop%22%20data-input-type%3D%22first%22%3E%3Cinput%20type%3D%22text%22%20id%3D%22first_3%22%20name%3D%22q3_name%5Bfirst%5D%22%20class%3D%22form-textbox%22%20data-defaultvalue%3D%22%22%20autoComplete%3D%22section-input_3%20given-name%22%20size%3D%2210%22%20data-component%3D%22first%22%20aria-labelledby%3D%22label_3%20sublabel_3_first%22%20value%3D%22%22%20%2F%3E%3Clabel%20class%3D%22form-sub-label%22%20for%3D%22first_3%22%20id%3D%22sublabel_3_first%22%20style%3D%22min-height%3A13px%22%3EFirst%20Name%3C%2Flabel%3E%3C%2Fspan%3E%3Cspan%20class%3D%22form-sub-label-container%22%20style%3D%22vertical-align%3Atop%22%20data-input-type%3D%22last%22%3E%3Cinput%20type%3D%22text%22%20id%3D%22last_3%22%20name%3D%22q3_name%5Blast%5D%22%20class%3D%22form-textbox%22%20data-defaultvalue%3D%22%22%20autoComplete%3D%22section-input_3%20family-name%22%20size%3D%2215%22%20data-component%3D%22last%22%20aria-labelledby%3D%22label_3%20sublabel_3_last%22%20value%3D%22%22%20%2F%3E%3Clabel%20class%3D%22form-sub-label%22%20for%3D%22last_3%22%20id%3D%22sublabel_3_last%22%20style%3D%22min-height%3A13px%22%3ELast%20Name%3C%2Flabel%3E%3C%2Fspan%3E%3C%2Fdiv%3E%0A%20%20%20%20%20%20%20%20%3C%2Fdiv%3E%0A%20%20%20%20%20%20%3C%2Fli%3E%0A%20%20%20%20%20%20%3Cli%20class%3D%22form-line%22%20data-type%3D%22control_email%22%20id%3D%22id_4%22%3E%3Clabel%20class%3D%22form-label%20form-label-top%20form-label-auto%22%20id%3D%22label_4%22%20for%3D%22input_4%22%20aria-hidden%3D%22false%22%3E%20Email%20%3C%2Flabel%3E%0A%20%20%20%20%20%20%20%20%3Cdiv%20id%3D%22cid_4%22%20class%3D%22form-input-wide%22%20data-layout%3D%22half%22%3E%20%3Cspan%20class%3D%22form-sub-label-container%22%20style%3D%22vertical-align%3Atop%22%3E%3Cinput%20type%3D%22email%22%20id%3D%22input_4%22%20name%3D%22q4_email%22%20class%3D%22form-textbox%20validate%5BEmail%5D%22%20data-defaultvalue%3D%22%22%20autoComplete%3D%22section-input_4%20email%22%20style%3D%22width%3A310px%22%20size%3D%22310%22%20data-component%3D%22email%22%20aria-labelledby%3D%22label_4%20sublabel_input_4%22%20value%3D%22%22%20%2F%3E%3Clabel%20class%3D%22form-sub-label%22%20for%3D%22input_4%22%20id%3D%22sublabel_input_4%22%20style%3D%22min-height%3A13px%22%3Eexample%40example.com%3C%2Flabel%3E%3C%2Fspan%3E%20%3C%2Fdiv%3E%0A%20%20%20%20%20%20%3C%2Fli%3E%0A%20%20%20%20%20%20%3Cli%20class%3D%22form-line%22%20data-type%3D%22control_button%22%20id%3D%22id_2%22%3E%0A%20%20%20%20%20%20%20%20%3Cdiv%20id%3D%22cid_2%22%20class%3D%22form-input-wide%22%20data-layout%3D%22full%22%3E%0A%20%20%20%20%20%20%20%20%20%20%3Cdiv%20data-align%3D%22center%22%20class%3D%22form-buttons-wrapper%20form-buttons-center%20%20%20jsTest-button-wrapperField%22%3E%3Cbutton%20id%3D%22input_2%22%20type%3D%22submit%22%20class%3D%22form-submit-button%20form-submit-button-gray-900%20submit-button%20jf-form-buttons%20jsTest-submitField%20legacy-submit%22%20data-component%3D%22button%22%20data-content%3D%22%22%3ESubmit%3C%2Fbutton%3E%3C%2Fdiv%3E%0A%20%20%20%20%20%20%20%20%3C%2Fdiv%3E%0A%20%20%20%20%20%20%3C%2Fli%3E%0A%20%20%20%20%20%20%3Cli%20style%3D%22display%3Anone%22%3EShould%20be%20Empty%3A%20%3Cinput%20type%3D%22text%22%20name%3D%22website%22%20value%3D%22%22%20type%3D%22hidden%22%20%2F%3E%3C%2Fli%3E%0A%20%20%20%20%3C%2Ful%3E%0A%20%20%3C%2Fdiv%3E%0A%20%20%3Cscript%3E%0A%20%20%20%20JotForm.showJotFormPowered%20%3D%20%22new_footer%22%3B%0A%20%20%3C%2Fscript%3E%0A%20%20%3Cscript%3E%0A%20%20%20%20JotForm.poweredByText%20%3D%20%22Powered%20by%20Jotform%22%3B%0A%20%20%3C%2Fscript%3E%0A%20%20%3Cscript%3E%0A%20%20%20%20JotForm.accessible%20%3D%20true%3B%0A%20%20%3C%2Fscript%3E%0A%20%20%3Cscript%20src%3D%22https%3A%2F%2Fcdn.jotfor.ms%2Fs%2Fumd%2Fec39bbf2214%2Ffor-accessibility-enhancer.js%22%20type%3D%22text%2Fjavascript%22%3E%3C%2Fscript%3E%0A%20%20%3Cinput%20type%3D%22hidden%22%20class%3D%22simple_spc%22%20id%3D%22simple_spc%22%20name%3D%22simple_spc%22%20value%3D%22251316737507054%22%20%2F%3E%0A%20%20%3Cscript%20type%3D%22text%2Fjavascript%22%3E%0A%20%20%20%20var%20all_spc%20%3D%20document.querySelectorAll%28%22form%5Bid%3D%27251316737507054%27%5D%20.si%22%20%2B%20%22mple%22%20%2B%20%22_spc%22%29%3B%0A%20%20%20%20for%20%28var%20i%20%3D%200%3B%20i%20%3C%20all_spc.length%3B%20i%2B%2B%29%0A%20%20%20%20%7B%0A%20%20%20%20%20%20all_spc%5Bi%5D.value%20%3D%20%22251316737507054-251316737507054%22%3B%0A%20%20%20%20%7D%0A%20%20%3C%2Fscript%3E%0A%3C%2Fform%3E%3Cscript%20type%3D%22text%2Fjavascript%22%3EJotForm.ownerView%3Dtrue%3B%3C%2Fscript%3E%3Cscript%20type%3D%22text%2Fjavascript%22%3EJotForm.isNewSACL%3Dtrue%3B%3C%2Fscript%3EMeet with our team to discuss your next study.Agilex Biolabs HQ 31 Dalgleish Street Thebarton SA 5031Agilex Brisbane Facility 2404 Logan Road Eight Mile Plains QLD 4113Australia +61 8 8302 8787 USA +1 800 247 1909 China +86 21 8036 9483 South Korea +82 80 812 1255Study Related EnquiriesGeneral Enquiries - [Bio-Blog](https://www.agilexbiolabs.com/bio-blog/): The Association of the British Pharmaceutical Industry, which is the UK’s equivalent to Medicines Australia, recently issued a report concluding, “Pharmaceutical companies are increasingly placing their trials in other countries (e.g., Australia and Spain).” - [Privacy Policy](https://www.agilexbiolabs.com/privacy-policy/): We only collect personal information that is reasonably necessary for our business activities. - [Webinars](https://www.agilexbiolabs.com/webinars-list/) - [Events](https://www.agilexbiolabs.com/events/): Hilton San Francisco Union SquareAttendees: Stephen McIntyre, Cameron Smith, Mallory Jolly, Jonah Michaelian, Gene RaySan Francisco Marriott MarquisAttendees: Gene Ray and Mallory JollySan Francisco Marriott MarquisAttendees: Jonah Michaelian and Mallory JollyHyatt Regency, DallasAttendee: Jonah MichaelianCOEX, SEOULAttendees: Amilia Wee and Xhin Yin NgoShanghai Zhangjiang Science HallAttendees: Amilia Wee and Xhin Yin NgoSan Diego Convention and Exhibition CenterAttendees: Steve McIntyre, Jonah Michaelian, Gene Ray, Ricky Matias, Amilia Wee and Morgan Evans,Taipei Nangang Exhibition CenterAttendees: Xhin Yin Ngo, - [Testimonials and Client Feedback](https://www.agilexbiolabs.com/testimonials/): 2024 / 2025 Client Feedback OUR VALUES THE TRUSTED EXPERTS - [Services](https://www.agilexbiolabs.com/services/) - [Our Team](https://www.agilexbiolabs.com/our-team/) - [Our Services](https://www.agilexbiolabs.com/our-services/): Pharmacokinetics (PK) is the study of what the body does to a drug during a clinical study and refers to the time course of absorption, bioavailability, distribution, metabolism and excretion of the drug.Pharmacodynamics (PD) is the study of the biochemical, physiological and molecular effects of a therapeutic on the body. PD assessments provide vital information on the receptor binding, pathways, genes, RNA and proteins.Biomarkers are playing an increasingly important role in clinical studies where they can provide essential efficacy, safety, and pathology data around the drug and indication being investigated.Let the Agilex team manage the life cycle of your samples from end to end. If your trial is a multi-site program, Agilex can manage the kit production to your sites of choice.Off the shelf assays are a great way to save time and money for your bioanalytical package. Review our ever growing list of accessible assays and discuss with our technical team about speedy setup. - [About Us](https://www.agilexbiolabs.com/about-us/): Agilex Biolabs is Australia’s most advanced regulated bioanalytical laboratory, serving global biotechnology and pharmaceutical companies with exceptional scientific support for preclinical and clinical trials. With a legacy spanning more than 30 years, we are recognized internationally for our precision, responsiveness, and dedication to excellence in bioanalysis. - [Careers at Agilex Biolabs](https://www.agilexbiolabs.com/careers/): Agilex Biolabs is Australia’s largest and most technologically advanced regulated bioanalytical laboratory offering both large and small molecule drug development support with the recent expansion into the cell & gene therapy space. For over 30 years, we have been recognised for our scale and proven track record for fast start up and reliable data. - [News & Webinars](https://www.agilexbiolabs.com/company-news/) - [News](https://www.agilexbiolabs.com/news/) - [Contacts](https://www.agilexbiolabs.com/contacts/): ABOUT US Address Agilex Biolabs HQ 31 Dalgleish Street Thebarton SA 5031, Australia Agilex Brisbane Bioanalytical Laboratory QIMR, 300 Herston Rd, Herston QLD 4006, Australia Phone Australia +61 8 8302 8787 USA +1 800 247 1909 China +86 21 8036 9483 South Korea +82 80 812 1255 Email Study Related Enquiries bd@agilexbiolabs.com General Enquiries info@agilexbiolabs.com Book a Meeting - [Home](https://www.agilexbiolabs.com/): Agilex Biolabs is Australia’s leading bioanalytical laboratory, serving global biotechnology and pharmaceutical companies with exceptional scientific support for preclinical and clinical trials. With a legacy spanning almost 30 years, we are recognized internationally for our precision, responsiveness, and dedication to excellence in bioanalysis. ## Services - [Pharmacodynamics (PD)](https://www.agilexbiolabs.com/service/pharmacodynamics/): Over 28 years of experience in developing and validating robust compliant immunoassay, immunogenicity, and cell-based assays to support nonclinical and clinical programs. - [Pharmacokinetics (PK)](https://www.agilexbiolabs.com/service/pharmacokinetics/): Experts in overcoming bioanalytical challenges from new chemical and biological entities. - [Off the Shelf Assays](https://www.agilexbiolabs.com/service/off-the-shelf-assays/): pre-designed and pre-validated assays, often available in kit form, that are ready for use without the need for extensive development or optimization - [Central Lab Services](https://www.agilexbiolabs.com/service/central-lab-services/): Agilex offers a wide range of kit productions and logistics services to explore - [Biomarkers](https://www.agilexbiolabs.com/service/biomarkers/): Determine key insights into a therapeutic’s efficacy, safety profile, and mechanism of action. ## Team - [Stephen McIntyre](https://www.agilexbiolabs.com/team/stephen-mcintyre/): Stephen has a proven record of success in executive leadership, producing transformational expansions and enabling Australian companies to establish and refine their global reach in the pathology and healthcare sectors. His background working in complex and highly regulated markets, both in Australia and globally, paired with a strong track record for facilitating successful mergers and acquisitions, makes him uniquely qualified to lead Agilex towards continued growth and success. - [Jason Valentine](https://www.agilexbiolabs.com/team/jason-valentine/): As the Chief Strategy Officer of Agilex Biolabs, and previously the founding CEO of CPR Pharma Services, Jason’s passion for scientific excellence ensured that Agilex Biolab’s exacting scientific standards are maintained. - [Cameron Smith](https://www.agilexbiolabs.com/team/cameron-smith/): Cameron has over 14 years in the CRO industry, specializing in preclinical drug development (originally, he began with pharmacology). - [Kim Salvatore](https://www.agilexbiolabs.com/team/kim-salvatore/): Kim Salvatore’s (BSc (Hons Organic Chemistry), GradCert PM) industry experience spans 15+ years working in the Pharma & BioPharma industries across new product development, bioanalysis and toxicology projects. Kim joined Agilex in 2022 and is credited with establishing the project management function of the business. - [Matthew Evans](https://www.agilexbiolabs.com/team/matthew-evans/): With over 20 years experience in FDA and TGA regulated pharmaceutical manufacture, quality control and quality assurance, Matthew currently serves as the Head of Large Molecule at Agilex Biolabs. - [Morgan Evans](https://www.agilexbiolabs.com/team/morgan-evans/): With over a decade of progressive experience spanning roles from laboratory technician to Senior Scientific Advisor, Morgan Evans currently serves as Chief Scientific Officer at Agilex Biolabs, a position he has held since 2025. In this pivotal role, he ensures the scientific integrity of studies conducted across all project teams, shapes the scientific strategy at an executive level, and collaborates closely with clients to design effective bioanalytical strategies. Additionally, he spearheads the development of Agilex’s innovation framework, identifying and nurturing pioneering ideas that maintain Agilex’s competitive edge in the industry. - [Jane Harris](https://www.agilexbiolabs.com/team/jane-harris/): Jane is an experienced and passionate People and Culture leader who brings a value and people-focused approach to her leadership.  She is highly experienced in leading initiatives at strategic and operational levels across the full employee lifecycle. Jane has successfully managed programs to enhance employee engagement, talent acquisition, performance, retention, and succession planning. - [David McGown](https://www.agilexbiolabs.com/team/david-mcgown/): David joined Agilex in 2023 as Head of Finance. He brings a wealth of knowledge to fast growing businesses with a global outreach.  He is experienced at board and executive level, with strong financial and management skills and organisational development focus. David has a Bachelor of Economics, is a Chartered Accountant and graduate of the Institute of Company Directors. He has over 25 years of experience working with international accounting firms and senior executive roles across a variety of industries providing the necessary skills to adapt swiftly to new and challenging environments. - [Agata Michalak](https://www.agilexbiolabs.com/team/agata-michalak/): Born in Poland, Agata earned a Master’s degree in Biotechnology before relocating to the United Kingdom to pursue a career in the life sciences industry. Over the years, Agata has gained extensive experience in animal and human diagnostics, the agricultural sector, histology, and immunochemistry, with a strong focus on bioanalysis in drug development. - [Kirsten Wilcox](https://www.agilexbiolabs.com/team/kirsten-wilcox/): Kirsten Wilcox (BSc) has 12 years of experience in regulatory bioanalysis and joined Agilex Biolabs in 2020. When she joined the LCMS group, she was responsible for ensuring the smooth operation of the analytical teams throughout the drug development process, from validation to sample analysis. Her goal was to ensure that work was performed to meet regulatory standards and delivered promptly to support the progression of drugs along their clinical pathways. In her current role, she is dedicated to advancing toxicology and immunobiology in Australia. She aims to collaborate with leaders in these scientific fields to facilitate the successful launch of promising drugs into clinical settings and to maximize the insights gained from clinical trials, ultimately enhancing patient outcomes. - [Dr Patrick Hughes](https://www.agilexbiolabs.com/team/patrick-hughes-phd-and-nhmrc-fellow/): Dr Patrick Hughes (B.Sc (Hons Pharmacology) 1999, PhD 2008) has over 15 years post-doctoral experience in immunology and molecular biology research. He joined Agilex Biolabs in 2020 to establish the cell based and molecular services at Agilex, including flow cytometry, PCR, Elispot, and functional cell-based assays from PBMC and whole blood. Patrick is driven by developing and performing assays to the highest standards. He particularly enjoys the collaborative nature of contract research where he aims to provide sponsors with the best solutions for their Immunobiology needs. - [Dr Jason Geue](https://www.agilexbiolabs.com/team/dr-jason-geue/): Dr Jason Geue, with a PhD in chemistry, brings 20+ years of expertise in bioanalysis. Since joining Agilex in 2011, he has been influential in developing robust LCMS assays for complex analytes, supporting both clinical and non-clinical trials.  Jason thrives on the collaborative nature of his role at Agilex, working closely with clients of all sizes to develop pragmatic assays that meet their specific needs within tight timelines. His dedication to a science-based approach ensures that every client receives tailored solutions that drive the success of their drug programs. - [Michael Romeo](https://www.agilexbiolabs.com/team/michael-romeo/): Michael leads Agilex's Project Management and Proposals functions, driving a client-focused service from pre-award through to project delivery. With over 10 years’ experience in the pharmaceutical, biotech, and clinical research sectors, he holds a Bachelor of Pharmaceutical Science along with postgraduate qualifications in both Business and Public Health. - [William Grenfell](https://www.agilexbiolabs.com/team/william-grenfell/): William leads Agilex’s IT department, driving innovation and reliability across in-house ITC services. With 26 years of experience in Clinical, Pharma, and BioPharma industries, he specialises in delivering secure, compliant, and governance-aligned information solutions. His career began as an IT consultant, working with clients nationwide for two decades, which shaped his passion for designing agile systems that stand up to real-world demands. William applies first principles thinking to build robust, scalable solutions and is committed to fostering collaboration across IT, privacy, and QA teams to protect client data and reputation. - [David Paterson](https://www.agilexbiolabs.com/team/david-paterson/): David Paterson is the Compliance & Quality Manager at Agilex Biolabs, bringing over 15 years of experience in regulated bioanalytical, pharmaceutical, and toxicology environments. Since joining Agilex in 2019, David has held progressive leadership roles in QA, before stepping into his current position in 2024.